Enhancing Signal Detection and Mitigating Placebo Response in Major Depressive Disorder Clinical Trials, Upcoming Webinar Hosted by Xtalks

Enhancing Signal Detection and Mitigating Placebo Response in Major Depressive Disorder Clinical Trials, Upcoming Webinar Hosted by Xtalks ...
Nasdaq

Q32 Bio reports results from SIGNAL-AA Phase 2a clinical trial

Q32 Bio (QTTB) announced topline results from the SIGNAL-AA Phase 2a signal finding clinical trial evaluating bempikibart, or ADX-914, which identified encouraging clinical activity in patients with ...
Seeking Alpha

Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata

-- SIGNAL-AA Part B exceeded target enrollment based on demand from patients; trial size increased to 33 patients -- WALTHAM, Mass., Oct. 21, 2025 /PRNewswire/ -- Q32 Bio Inc. (QTTB) ("Q32 Bio"), a ...
Hosted on MSN

Clinical AI Innovation: Biomedical Signal Processing Insights by Nishit Agarwal

Nishit Agarwal exemplifies excellence in Biomedical AI and Signal Processing with extensive experience in developing cutting-edge clinical AI solutions and biomarker development. His expertise spans ...